Featured news and headlines
The latest news and information for the University of Kansas.
American Museum Of Natural History New York United States Khorat Plateau Thailand General North Carolina
Source: ku.edu
📰 Bryan Stuart News
Bryan Stuart News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Bryan Stuart. Real-time updates on events, politics, business and more.
Atavistik Bio Raises Additional $40M in Funding
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Source: finsmes.com
Americans' Approval of Unions Could Help Turn the Tide Against Inequality
CityWatch is published 24/7 with special e-news blasts on Monday and Thursday evening, with Extras as appropriate around special events such as elections or imp
Source: citywatchla.com
Fulcrum Therapeutics tabs Alex Sapir as CEO
Following the transaction, the new company will be responsible for developing and commercializing zagociguat and CY3018.
Source: mmm-online.com
FULCRUM THERAPEUTICS, INC. : Results of Operations and Financial Condition, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)
Item 2.02 Results of Operations and Financial Condition. To the extent applicable to this Item, the disclosure set forth in Item 8.01 is incorporated by reference herein. Item 5.02 Departure of... | January 4, 2023
United States Robertj Gould Bryan Stuart Johns Hopkins University Hemoshear Therapeutics Inc University Of Iowa
Source: marketscreener.com
Fulcrum Therapeutics : Announces Second Quarter 2022 Financial Results and Business Update - Form 8-K
Fulcrum TherapeuticsAnnounces Second Quarter 2022 Financial Results and Business Update - Presented initial data from Phase 1b trial in sickle cell disease ,... | August 11, 2022
Source: marketscreener.com
Fulcrum Therapeutics Announces Proof-of-Concept for FTX-6058 in Sickle Cell Disease Based on ...
- Achieved up to 6.3% hemoglobin F (HbF) induction in initial subjects in first cohort; HbF was increasing at last measured timepoint
Source: kentuckytoday.com
Fulcrum Therapeutics' (FULC) CEO Bryan Stuart on Q1 2022 Results - Earnings Call Transcript
Fulcrum Therapeutics, Inc. (NASDAQ:NASDAQ:FULC) Q1 2022 Earnings Conference Call May 9, 2022, 8:00 am ET Company Participants Naomi Aoki - SVP, Corporate Communications & IR Bryan...
Source: seekingalpha.com
Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results
03.03.2022 - – Clear path forward for Phase 3 REACH trial with losmapimod in FSHD; Trial expected to begin in 2Q 2022 – – On track to report initial data from Phase 1b trial with FTX-6058 in sickle cell disease in 2Q 2022 – – Conference call scheduled for ...
Source: wallstreet-online.de
Fulcrum Therapeutics® Announces Additional HBG mRNA Induction from Higher Dose Cohorts in Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease and New Preclinical Mechanism Data
Achieved mean 5.6-fold HBG mRNA induction at 20mg and mean 6.2-fold at 30mg after 14 days of once-daily dosing, further supporting potential of FTX-6058 to provide a functional cure Continues to be... | December 6, 2021
Source: marketscreener.com